BioMarin Pharmaceutical (BMRN) Stock Forecast & Price Target

BioMarin Pharmaceutical is viewed positively because the company has turned a major competitive threat in achondroplasia into a royalty-bearing asset, securing 20% of U.S. YUVIWEL net sales and 18% in the EU, Brazil, and South Korea through May 2030, while also resolving litigation uncertainty around its IP. The arrangement is strategically attractive because YUVIWEL’s once-weekly schedule versus VOXZOGO’s once-daily dosing could improve adoption in infants, and BioMarin’s established VOXZOGO franchise already generated $253M in 2Q26, up 15% sequentially. These royalties, modeled at $12M in 2026E and rising thereafter, provide time and capital flexibility for BioMarin’s expanding pipeline, including BMN 333 and other early-stage programs, while supporting earnings growth and reducing reliance on a single product.

BioMarin Pharmaceutical is weighed down by concentrated competitive risk in its skeletal-dysplasia franchise, where VOXZOGO generated $253M in 2Q26 but faces faster switching and new-start share loss to YUVIWEL and other ACH rivals. Although the settlement preserves 18% to 20% retained economics on YUVIWEL sales through May 2030, it only slows revenue erosion rather than eliminating it, while the company still depends on weaker-than-expected uptake or regulatory execution in HCH to avoid further pressure. With an estimated ~$14.0B EV, about $3.5B of debt by end-3Q27, and BMN 333 still needing clear clinical differentiation, the fundamental setup remains exposed to franchise decay and an early-stage pipeline that may not offset it.